Treatment of lipids and type 2 diabetes
Abstract The development of type 2 diabetes is increasing in epidemic proportions. There is a significant risk for cardiovascular disease, which is the most prevalent and detrimental complication for the diabetic population. Serum lipid abnormalities are common in patients with diabetes, and due to this increased vascular risk, it is recommended to aggressively treat the hyperlipidemia. Therefore, intensive lipid-lowering therapy should be used for primary and secondary prevention against macrovascular complications for patients with type 2 diabetes. In this article some of the key studies justifying the need for lipid reduction in patients with type 2 diabetes are reviewed and practical guidelines for management of the dyslipidemia are suggested..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2004 |
|---|---|
| Erschienen: |
2004 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Current cardiology reports - 6(2004), 6 vom: Nov., Seite 443-450 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hermayer, Kathie L. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Absolute Risk Reduction |
|---|
| Anmerkungen: |
© Current Science Inc. 2004 |
|---|
| doi: |
10.1007/s11886-004-0053-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2028914742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2028914742 | ||
| 003 | DE-627 | ||
| 005 | 20230402071210.0 | ||
| 007 | tu | ||
| 008 | 200819s2004 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11886-004-0053-4 |2 doi | |
| 035 | |a (DE-627)OLC2028914742 | ||
| 035 | |a (DE-He213)s11886-004-0053-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Hermayer, Kathie L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of lipids and type 2 diabetes |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Current Science Inc. 2004 | ||
| 520 | |a Abstract The development of type 2 diabetes is increasing in epidemic proportions. There is a significant risk for cardiovascular disease, which is the most prevalent and detrimental complication for the diabetic population. Serum lipid abnormalities are common in patients with diabetes, and due to this increased vascular risk, it is recommended to aggressively treat the hyperlipidemia. Therefore, intensive lipid-lowering therapy should be used for primary and secondary prevention against macrovascular complications for patients with type 2 diabetes. In this article some of the key studies justifying the need for lipid reduction in patients with type 2 diabetes are reviewed and practical guidelines for management of the dyslipidemia are suggested. | ||
| 650 | 4 | |a Statin | |
| 650 | 4 | |a Pravastatin | |
| 650 | 4 | |a Fenofibrate | |
| 650 | 4 | |a Ezetimibe | |
| 650 | 4 | |a Absolute Risk Reduction | |
| 773 | 0 | 8 | |i Enthalten in |t Current cardiology reports |d Current Medicine Group, 1999 |g 6(2004), 6 vom: Nov., Seite 443-450 |w (DE-627)333035941 |w (DE-600)2055373-0 |x 1523-3782 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2004 |g number:6 |g month:11 |g pages:443-450 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11886-004-0053-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2004 |e 6 |c 11 |h 443-450 | ||